Chelle, Pierre
Yeung, Cindy H. T.
Bonanad, Santiago
Morales Muñoz, Juan Cristóbal
Ozelo, Margareth C.
Megías Vericat, Juan Eduardo
Iorio, Alfonso
Spears, Jeffrey
Mir, Roser
Edginton, Andrea
Funding for this research was provided by:
Grifols SA
Article History
Received: 1 December 2018
Accepted: 11 April 2019
First Online: 21 May 2019
Change Date: 13 July 2019
Change Type: Correction
Change Details: The article Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients, written by Pierre Chelle, Cindy H. T. Yeung, Santiago Bonanad, Juan Cristóbal Morales Muñoz, Margareth C. Ozelo, Juan Eduardo Megías Vericat, Alfonso Iorio, Jeffrey Spears, Roser Mir, Andrea Edginton, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 21 May 2019 without open access.
Compliance with ethical standards
:
: AI.’s Institution has received project based funding via research or service agreements with Bayer, CSL, Grifols, NovoNordisk, Octapharma, Pfizer, Roche and Shire (formerly Baxter and Baxalta), including funds to support the data collection and analysis of the reported in this manuscript. M.O. has received grant/research support from Bioverativ, Novo Nordisk, Pfizer, Roche and Shire; has served on advisory boards for Shire, Novo Nordisk, Pfizer, and Roche; and has served on speakers’ bureau for Shire, Novo Nordisk, Pfizer, Grifols and Roche. S.B. has received speaker fees from Roche, SOBI, Shire, Grifols, Bayer, Octapharma, Pfizer, CSL Behring, NovoNordisk, and Bioverativ; investigational grants from Grifols, Bayer, Shire, Novoordisk, and Pfizer; Ad boards fees from Roche, Pfizer, Shire, SOBI, CSL Behring, and Bayer. J.S and R.M are employees of Grifols.